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Abstract 
Background: Primary hyperparathyroidism (PHPT) is an endocrine disease that poses a risk 
for cardiac arrhythmias. Atrial electromechanical delay (EMD) has been known as an early 
marker of atrial fibrillation (AF). This study aimed to evaluate the atrial EMD in PHPT. 
Material and methods: Fifty PHPT patients (45 females, 5 males) aged 30–75 years and 38 
controls (35 females, 3 males) aged 31-73 years were included in the study. Atrial EMD 
parameters were measured by using tissue Doppler imaging (TDI). Inter-atrial EMD was 
calculated as the difference between PA lateral and PA tricuspid; intra-atrial EMD was 
calculated as the difference between PA septum and PA tricuspid, and left-atrial EMD was 
calculated as the difference between PA lateral and PA septum. 
Results: Atrial EMD parameters (PA lateral, PA septum, PA tricuspid) significantly increased 
in the PHPT group compared to the control group (p < 0.001, for all). Also, inter-atrial and 
intra-atrial EMD were higher in the PHPT group than in the control group (p < 0.001, for all). 
In correlation analysis, calcium was closely associated with PA lateral (r = 0.749, p < 0.001), 
PA septum (r = 0.735, p < 0.001), inter-atrial EMD (r = 0.807, p < 0.001), and intra-atrial EMD 
(r = 0.838, p < 0.001). The same correlation relationship was seen between PTH levels with PA 
lateral (r = 671, p < 0.001), PA septum (r = 0.660, p < 0,001), inter-atrial EMD (r = 0.674, p < 
0.001), and intra-atrial EMD (r = 0.732, p < 0.001). 
Conclusions: Atrial EMD parameters were prolonged in PHPT. The measurement of atrial 
EMD parameters might be used in determining the risk of AF development in PHPT. 
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Introduction 
Primary hyperparathyroidism (PHPT) is an endocrine disease characterized by excessive 
release of parathyroid hormone (PTH), resulting in dysregulation of calcium (Ca) metabolism 
[1]. Although clinical practice focuses more on adverse effects such as renal complications and 
osteoporosis in hyperparathyroidism, PHPT is associated with increased cardiovascular 
morbidity and mortality [2]. 
Atrial fibrillation (AF) is a vital heart rhythm disorder common in clinical practice, which 
causes haemodynamic disorders, frequent hospitalizations, and thromboembolic events, and it 
affects 1-2% of the general population [3]. Although the exact mechanisms causing AF are not 
fully understood, hypertension, heart failure, diastolic dysfunction, endothelial dysfunction, and 
left ventricular hypertrophy play an essential role in the pathogenesis of AF [3, 4]. Side effects 
such as hypertension, diastolic dysfunction, endothelial dysfunction, left ventricular 
hypertrophy can also be seen in PHPT disease [2]. Therefore, these patients may be at increased 
risk of newly developing AF. 
The atrial conduction time (ACT) represents the interval between sinus impulses and atrial 
mechanical contraction. It may be measured noninvasively by tissue Doppler imaging (TDI) 
(5) as an alternative to invasive electrophysiological measurements. The prolongation of intra- 
and inter-atrial conduction time, called atrial electromechanical delay (EMD), is associated with 
atrial fibrillation frequency and sensitivity [6]. 
To the best of our knowledge, atrial conduction abnormalities have not been previously 
evaluated in patients with PHPT. Therefore, we aimed to assess the atrial conduction time in 
PHPT patients with TDI, a noninvasive method. Also, we wanted to investigate whether there 




Material and methods 
The study was carried out in Kayseri State Hospital, Endocrinology and Cardiology clinics from 
January 2019 to July 2020. Fifty PHPT patients (45 females, 5 males) aged 30–75 years and 38 
controls (35 females, 3 males) aged 31–73 years were included in the study. 
A detailed medical history from all patients, physical examination, 12-lead electrocardiography, 
a complete blood count, and a serum biochemistry test were performed. The presence of 
classical cardiovascular risk factors, including hypertension, diabetes mellitus, and 
hyperlipidaemia, was assessed. Detailed transthoracic echocardiographic examination was 
performed on all patients. There were no atrial or ventricular conduction anomalies in both the 
patient group and the control group in ECG. Also, none of the patients included in the study 
had a history of paroxysmal AF. 
Patients with a history of ischaemic heart disease, patients with non-sinus rhythm and 
peacemaker presence, patients with segmental or global wall motion disorders, patients with 
evidence of moderate to severe valvular heart disease on echocardiography, and patients with 
structural heart disease, multiple endocrine neoplasms, parathyroid cancer, thyroid cancer, or 
hyperparathyroidism-jaw tumour syndrome, renal failure, and severe comorbidities were 
excluded from the study. 
Type 2 diabetes mellitus (T2DM), hypertension (HT), and hyperlipidaemia were defined as 
previously described [7]. 
 
Echocardiography  
Conventional echocardiography was performed with two-dimensional, M-mode, pulsed wave, 
continuous, colour Doppler and tissue Doppler imaging (TDI) using a Philips Epiq 7 ultrasound 
system (Philips, Andover, Mass., USA). Simultaneous ECG recording was done. All patients 
were in sinus rhythm at the time of examination. Conventional echocardiographic images were 
obtained from the parasternal and apical views according to the guidelines of the American 
Society of Echocardiography [8]. M-mode echocardiography measured left ventricular (LV) 
diameters and wall thickness from the parasternal views. Simpson’s method was used for the 
calculation of LV ejection fraction. While the left atrial area was measured from the apical 
view, LA diameter was measured from the parasternal long-axis view. Mitral inflow velocities 
were measured from apical views. Isovolumic relaxation time (IVRT) was obtained by 
measurements from pulsed-wave TDI velocities in the medial and lateral walls of the apical 
four-chamber view (an average between the two values). 
 
Atrial electromechanical time measurement  
TDI was performed using transducer frequencies of 3.5–4.0 MHz. The spectral pulsed Doppler 
signal filters were adjusted until a Nyquist limit of 15–20 cm/s was obtained. The minimal 
optimal gain was used. Myocardial TDI velocities [peak systolic (S’), early diastolic (E’), and 
late diastolic velocities (A’)] were measured with spectral pulsed Doppler from the apical four-
chamber view. The ultrasound beam slope did not exceed 15% to acquire the optimal angle of 
imaging. The monitor sweep speed was adjusted at 50–100 mm/s to optimize myocardial 
velocities' spectral display. Atrial EMD was defined as the time interval from the onset of atrial 
electrical activity (P wave on surface ECG) to the beginning of mechanical atrial contraction 
(late diastolic A wave) in TDI. All values were averaged over three consecutive beats. Atrial 
EMD was measured from the lateral mitral annulus, and was called ‘PA lateral’; from the septal 
mitral annulus it was called ‘PA septal’; and from the right ventricle tricuspid annulus it was 
called ‘PA tricuspid’. Inter-atrial EMD was calculated as the difference between PA lateral and 
PA tricuspid, intra-atrial EMD was calculated as the difference between PA septum and PA 
tricuspid, and left-atrial EMD was calculated as the difference between PA lateral and PA 
septum [5].  
A total of 20 participants, 10 from the patient group and 10 from the control group, were 
randomly selected to evaluate the intra-observational variability. Measurements were repeated 
under the same baseline conditions. Intra-observer variability was 4% for lateral PA, 4.4% for 
septal PA, and 5.1% for tricuspid PA, respectively. 
 
Statistical analysis  
Statistical analyses were performed using SPSS Statistics Package version 21.0 (SPSS Inc., 
Chicago, IL, USA) for Windows. The distribution characteristics of the data were determined 
by using the Kolmogorov-Smirnov test. The independent samples t-test was used to compare 
normally distributed quantitative variables, and the Mann-Whitney U test was used to compare 
non-normally distributed quantitative variables. The χ2 test was used for univariate analysis of 
the categorical variables. The variables were given as mean ± SD; categorical variables were 
defined as percentage. The median and interquartile ranges were given when the variable did 
not follow a normal distribution. Correlation analyses were performed using Spearman's 
coefficient of correlation. A probability value of p < 0.05 was considered significant, and two-
tailed p-values were used for all statistics. 
 
Results 
The baseline characteristics of patients and controls are given in Table 1. The PHPT group’s 
and control group’s average ages were 56.9 (49–68) and 56.8 (49–66) years, respectively. There 
were no significant differences between groups regarding age, gender, hypertension, diabetes 
mellitus, hyperlipidaemia, and smoking. 
Echocardiographic and atrial electromechanically time parameters are shown in Table 2. LV 
systolic and diastolic diameters, left atrial diameter and area, interventricular septum, posterior 
wall thickness, and LV ejection fraction were similar in the two groups. 
There was no difference between PHPT and healthy subjects in cardiovascular function 
parameters, except for IVRT, which was significantly longer in PHPT patients and indicated 
abnormal LV relaxation (86.05 ± 10.39 vs. 100.15 ± 9.93, p < 0.001). 
Atrial EMD parameters (PA lateral, PA septum, PA tricuspid) significantly increased in the 
PHPT group compared to the control group (76.62 ± 6.78 vs. 64.13 ± 8.03, 64.13 ± 4.87 vs. 
53.97 ± 5.98, 47.09 ± 6.60 vs. 43.55 ± 7.38, p < 0.001, p < 0.001, p < 0.001, respectively). Also, 
inter-atrial and intra-atrial EMD were higher in the PHPT group than in the control group (29.52 
± 9.12 vs. 20.57 ± 8.63, 17.03 ± 7.78 vs. 10.42 ± 6.27, p < 0.001, p < 0.001, respectively). Left 
atrial EMD was higher in the PHPT group, but it did not reach significance (12.49 ± 7.74 vs. 
10.15 ± 8.05, p = 0.171) (Fig. 1). 
Biochemical parameters are shown in Table 3. Serum phosphorus was significantly lower in 
the PHPT group than in the control group (median 3.72, interquartile range 3.5-4.0 vs. median 
2.62, interquartile range of 2.3-2.9, p < 0.001). On the other hand, calcium and parathyroid 
hormone levels were higher in the PHPT group than in the control group (median 10.86, 
interquartile range 10.5 to 11.2 vs. median 9.16, interquartile range 8.7 to 9.5: median 251.8, 
interquartile range 139.7 to 255.5 vs. median 35.6, interquartile range 31.5 to 41.0 p < 0.001, p 
< 0.001, respectively). Other blood parameters were similar between the two groups (Tab. 3). 
In correlation analysis, calcium was closely associated with PA lateral (r = 0.749, p < 0.001), 
PA septum (r = 0.735, p < 0.001), inter-atrial EMD (r = 0.807, p < 0.001), and intra-atrial EMD 
(r = 0.838, p < 0.001) (Fig. 2).  
There was the same correlation relationship between PTH levels with PA lateral (r = 0.671, p 
< 0.001), PA septum (r = 0.660, p < 0.001), inter-atrial EMD (r = 0.674, p < 0.001), and intra-
atrial EMD (r = 0.732, p < 0.001) (Fig. 3). 
 
Discussion 
This study is the first to show that both intra-atrial and inter-atrial conduction times were 
prolonged in PHPT patients. Also, we found that both intra-atrial EMD and inter-atrial EMD 
were significantly correlated with calcium and PTH levels. 
As is known, PHPT is an endocrinological disease that is typically characterized by high or 
non-suppressed parathyroid hormone levels (PTH) together with elevated serum calcium levels 
[1]. As far as we know, in the literature there are no ECG and echocardiography studies 
conducted to assess atrial arrhythmia risk in PHPT patients. Although hypercalcaemia is well 
known to cause cardiac conduction disturbances and arrhythmias, surprisingly, follow-up 
studies of this disease's long-term cardiovascular results have not been conducted. Due to the 
physiological effects of both parathyroid hormone (PTH) and calcium on the cardiomyocyte, 
cardiac conduction system, and pancreatic beta cells, disorders such as hypertension, 
arrhythmias, left ventricular hypertrophy, heart failure, glucose metabolism disorder, and 
metabolic syndrome can be seen throughout the disease [9]. Furthermore, studies investigating 
the effects of PHPT on the cardiovascular system have shown impairment in endothelial and 
vascular functions [10]. In addition to all these effects, increased sympathetic activity and 
activation of the renin-angiotensin and aldosterone system (RAS) due to increased 
catecholamines have been shown in PHPT [11, 12]. 
Furthermore, recent studies have shown impairment in LA functions of PHPT patients [13]. 
These undesirable effects that can be seen in PHPT are also known as risk factors for AF 
development [4]. The studies searching for PTH and calcium effects on the heart have shown 
that both cause changes in both endothelial cells and myocardial cells. PTH may have such 
effects on calcium; it may also be seen in connection with its effects on the cells directly [14, 
15]. Hypercalcaemia poses a risk for cardiac arrhythmia regardless of whether it occurs due to 
PHPT or other reasons [16, 17]. Although there are concerns over the development of more 
ventricular arrhythmia in PHPT, atrial arrhythmia may also be observed in the course of the 
disease. 
Non-invasive measurement of atrial EMD by TDI has been found to be successful in evaluating 
the risk of AF as an alternative to invasive electrophysiological measurements [5]. Cui QQ et 
al. showed that the atrial conduction delay measured by TDI was significantly longer in patients 
with paroxysmal AF compared to the control group [18]. Roshanalli et al. showed that the atrial 
electromechanical interval is a predictor of AF developing after coronary artery bypass grafting, 
and preoperative administration of amiodarone to patients with a longer atrial 
electromechanical interval reduces the incidence of postoperative AF [19]. Previous studies 
have shown that atrial EMD is prolonged in many clinical disorders such as mitral stenosis, 
diabetes mellitus, hypertension, psoriasis, and inflammatory bowel disease [20–24]. Also, the 
incidence of AF in these diseases has increased significantly compared to the normal 
population. In conclusion, atrial EMD is prolonged in paroxysmal AF and is considered a 
predictor of new-onset AF [25]. Our study showed that intra-atrial and inter-atrial EMD, a 
technique that predicts the risk of future AF development, was significantly longer in patients 
with PHPT compared to controls.  
We also found a significant correlation between both inter-atrial EMD and intra-atrial EMD 
and calcium. In previous studies, the increase in calcium release from the sarcoplasmic 
reticulum in atrial myocytes was related to AF development [26, 27]. Although hypercalcaemia 
is well known to cause cardiac conduction disturbances and arrhythmias, clinical observations 
of conduction disturbances caused by hypercalcaemia are surprisingly rare. Case reports have 
shown various conduction disorders such as atrioventricular nodal conduction defects, sinus 
node disease, and atrial fibrillation, depending on the severity of hypercalcaemia in patients 
with PHPT; the reason for the prevalence of these disorders is unknown [28]. It is known that 
cardiac relaxation is impaired in individuals with hypercalcaemia as a result of its deleterious 
effects on the myocardium through the excessive increase of intracellular calcium or calcium 
accumulation in the myocardium [29]. Also, Curione et al. showed that hypercalcaemia 
developed adverse effects on cardiac electrical stability in patients with PHPT [30]. According 
to our results, hypercalcaemia may cause prolongation in atrial EMD by causing involvement 
in atrial conduction paths in addition to myocardial involvement. Therefore, we may think that 
hypercalcaemia plays an essential role in the prolongation of atrial EMD. This suggests that the 
increase in calcium levels in PHPT patients may be determinant for the possible development 
of AF. 
Another significant result of our study is that we found that PTH levels are associated with atrial 
EMD. PTH is vital for calcium haemostasis. However, PTH itself is now known to cause 
hypertrophy of cardiac myocytes and vascular smooth muscle even without hypercalcaemia. 
Moreover, parathyroid hormone accelerates the heart rate, an effect mediated by PTH's direct 
effect on the sinus node and conduction system. PTH also exerts inotropic effects, possibly due 
to increased coronary blood flow due to the vasodilatory effect of PTH on the coronary 
circulation [31]. Furthermore, biochemical blood measurements have revealed high cytokine 
levels in patients with elevated PTH levels [32]. This suggests that there is also an inflammatory 
process in PHPT patients. Because of all these effects, the possibility of developing arrhythmia 
secondarily to PTH increase may scale up. 
Furthermore, serum PHT levels have been associated with AF in recent studies [33–36]. 
Rienstra et al. have found that PTH levels were significantly higher in patients who develop 
atrial fibrillation [35]. Lee et al. showed in their public-based study that the increase in PTH 
levels increased AF incidence [36]. In the study conducted by Pepe and Cipriani et al., more 
frequent atrial extrasystole in 24-hour ECG monitoring of PHPT patients was determined. Such 
arrhythmias were shown to be reduced with a decrease in post-parathyroidectomy PTH levels 
[37]. The relevant effects of PTH consequently lead to the occurrence of electrical and structural 
remodelling in myocardial cells. These effects cause hypertrophy, fibrosis, and functional 
disorders in the cardiovascular structures in time and are suggested to have facilitated atrial 
arrhythmia. Therefore, we can think that PTH plays a vital role in prolonging atrial EMD, a 
well-known AF predictor. This suggests that the increase in PTH levels in PHPT patients may 
determine the possible development of AF. 
Although our study is not a follow-up study, we have observed that intra-atrial and inter-atrial 
EMD, a technique that predicts cardiac arrhythmias, was significantly longer in patients with 
PHPT. It was also found that there is a significant correlation between both inter-atrial EMD 
and intra-atrial EMD and calcium and PTH levels. In other words, both high PTH and high 
calcium levels seem to have the potential to cause arrhythmogenic effects. When our outcomes 
are considered with the literature, it suggests that PHPT patients are at risk for atrial fibrillation. 
As the European Society of Cardiology emphasized in the latest AF guidelines [38], it is very 
important to identify and manage risk factors and comorbidities that predispose to AF prior to 
the development of atrial remodelling and fibrosis. Identifying individuals, e.g. with PHPT, at 
higher risk of developing AF in the community could facilitate early AF detection. Thus, we 
think the results of this study are clinically important.  
This study has the following limitations: it is hard to estimate how long the participants have 
been exposed to calcium and PTH. Furthermore, as the number of participants is low, it is 
impossible to determine the PTH cut-off value concerning the level and exposure period of its 
cardiac effects. The orbit of the disease may change in presymptomatic patients and with an 
intervention in the level of hypercalcaemia. We looked at atrial EMD, a useful marker for AF 
development, but the development of AF has not been directly investigated. Long-term follow-
up is required to identify cases that will cause AF. 
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Figure 1. Change PA lateral–PA tricuspid, PA septal–PA tricuspid, PA lateral–PA septal 




Figure 2.A. Correlation between PA lateral and calcium count; B. Correlation between PA 
septum and calcium count; C. Correlation between PA lateral–PA tricuspid and calcium count; 




Figure 3.A. Correlation between PA lateral and parathormone (PTH) level; B. Correlation 
between PA septum and PTH level; C. Correlation between PA lateral–PA tricuspid and PTH 




Table 1. Baseline clinical and demographic features of the study groups 
Variables 
Control group 
(n = 38) 
PHPT 
(n = 50) 
p value 
Age (years) 56.9 (49-68) 56.8 (49-66) 0.990 
Male/female 3/35 5/45 0.734 
HT 16 (42%) 22 44%) 0.859 
DM 3 (7.8%) 5 (10%) 0.734 
Smoking 1 (2.6%) 2 (4%) 0.726 
Hyperlipidemia 8 (21%) 10 (20%) 0.903 
Data are expressed as mean ± standard deviation for normally distributed data and percentage (%) for 






Table 2. Echocardiography characteristics of the study population  
Variables 
Control group 
(n = 38) 
PHPT 
(n = 50) 
p value 
LA diameter [cm] 3.37 (3.1–3.6) 3.46 (3.2–3.7) 0.241 
LA area [ cm2] 21.2 ± 2.1 22 ± 2.1 0.095 
LVDD [cm] 4.71 ± 0.31 4.73 ± 0.45 0.816 
LVESD [cm] 3.05 ± 0.35 2.99 ± 0.37 0.405 
IVSD [cm] 1.06 (0.9–1.1) 1.08 (0.9–1.2) 0.584 
PWD [cm] 1.03 ± 0.07 1.07 ± 0.14 0.192 
LVEF (%) 66.89 ± 4.07 65.17 ± 4.32 0.061 
PA lateral [ms] 64.13 ± 8.03 76.62 ± 6.78 < 0.001 
PA septum [ms] 53.97 ± 5.98 64.13 ± 4.87 < 0.001 
PA tricuspid [ms] 43.55 ± 7.38 47.09 ± 6.60 < 0.001 
PA lateral–PA tricuspid  
(inter-atrial delay) 
20.57 ± 8.63 29.52 ± 9.12 < 0.001 
Pa septal–PA tricuspid 
(intra-atrial delay) 
10.42 ± 6.27 17.03 ± 7.78 < 0.001 
PA lateral–PA septal 
(left-atrial delay) 
10.15 ± 8.05 12.49 ± 7.74 0.171 
Mitral E velocity 77.2 ± 11.2 73.3 ± 12.2 0.121 
Mitral A velocity 59.8 ± 15.6 63.6 ± 9.9 0.167 
DT [ms] 166.47 ± 24.38 173.56 ± 36.58 0.303 
IVRT [ms] 86.05 ± 10.39 100.15 ± 9.93 < 0.001 
(S’) [cm/s] 10.89 ± 3.02 10.86 ± 2.40 0.956 
(E’) [cm/s] 13.52 ± 3.20 12.37 ± 2.68 0.068 
(A’) [cm/s] 9.78 ± 2.76 10.62 ± 2.09 0.107 
PHPT — primary hyperparathyroidism; LA — left atrium; LVDD — LV end-diastolic dimension; 
LVSD — LV end-systolic dimension; IVSD — interventricular septum thickness; PWD — posterior 
wall thickness; LVEF — LV ejection fraction; DT — deceleration time; IVRT — isovolumic relaxation 
time. Inter-atrial delay — PA lateral–PA tricuspid; Intra-atrial delay — PA septum–PA tricuspid; Left-
atrial delay — PA lateral–PA septum; S’ — systolic velocity from the mitral annulus; E’ — early 
diastolic velocity from the mitral annulus; A’ — late diastolic velocity from the mitral annulus 
 
 
Table 3. Comparison of baseline laboratory measurements among the study groups 
Data are expressed as mean ± standard deviation for normally distributed data and percentage (%) for 
categorical variables. PHPT — primary hyperparathyroidism; BMI — body mass index; PTH — 
parathyroid hormone; WBC — white blood cell 
 
Variables 
Control group  
(n = 38) 
PHPT 
(n = 50) 
p value 
BMI 27.57 ± 1.82 27.35 ± 2.11 0.619 
Systolic blood pressure [mmHg] 119.52 ± 10.53 121.01 ± 11.69 0.536 
Diastolic blood pressure [mmHg] 73.47 ± 7.30 74.01 ± 6.43 0.710 
Glucose [mg/dL] 92.71 ± 14.01 97.28 ± 15.70 0.161 
Creatinine [mg/dL] 0.84 ± 0.20 0.76 ± 0.22 0.074 
AST [U/L] 19.31 ± 6.12 19.60 ± 7.05 0.843 
ALT [U/L] 18.39 ± 7.12 19.70 ± 9.82 0.491 
Albumin [g/L] 3.97 ± 0.52 4.11 ± 0.28 0.214 
Calcium count [mg/dL] 9.16 (8.7–9.5) 10.86 (10.5–11.2)  < 0.001 
Phosphorus [mg/dL] 3.72 (3.5–4.0) 2.62 (2.3–2.9) < 0.001 
Vitamin D 20.97 ± 6.06 18.71 ± 7.57 0.135 
PTH, [ug/L] 35.6 (31.5–41.0) 251.8 (139.7–255.5) < 0.001 
WBC [103/uL] 7.68 ± 1.44 7.53 ± 1.69 0.653 
Haemoglobin [g/L] 14.03 ± 1.56 13.90 ± 1.20 0.639 
Platelet [/mm3] 265.97 ± 69.38 256.56 ± 68.86 0.528 
